

Ana Bobinac

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1820315/publications.pdf>

Version: 2024-02-01

18
papers

666
citations

840776

11
h-index

996975

15
g-index

18
all docs

18
docs citations

18
times ranked

825
citing authors

#	ARTICLE	IF	CITATIONS
1	Caring for and caring about: Disentangling the caregiver effect and the family effect. <i>Journal of Health Economics</i> , 2010, 29, 549-556.	2.7	153
2	Willingness to Pay for a Quality-Adjusted Life-Year: The Individual Perspective. <i>Value in Health</i> , 2010, 13, 1046-1055.	0.3	88
3	Health Effects in Significant Others. <i>Medical Decision Making</i> , 2011, 31, 292-298.	2.4	77
4	The Value of a QALY: Individual Willingness to Pay for Health Gains Under Risk. <i>Pharmacoeconomics</i> , 2014, 32, 75-86.	3.3	50
5	VALUING QALY GAINS BY APPLYING A SOCIETAL PERSPECTIVE. <i>Health Economics (United Kingdom)</i> , 2013, 22, 1272-1281.	1.7	49
6	What Influences Patients' Decisions When Choosing a Health Care Provider? Measuring Preferences of Patients with Knee Arthrosis, Chronic Depression, or Alzheimer's Disease, Using Discrete Choice Experiments. <i>Health Services Research</i> , 2015, 50, 1941-1972.	2.0	48
7	GET MORE, PAY MORE? An elaborate test of construct validity of willingness to pay per QALY estimates obtained through contingent valuation. <i>Journal of Health Economics</i> , 2012, 31, 158-168.	2.7	45
8	Inquiry into the Relationship between Equity Weights and the Value of the QALY. <i>Value in Health</i> , 2012, 15, 1119-1126.	0.3	43
9	The invisible hands made visible: recognizing the value of informal care in healthcare decision-making. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2008, 8, 557-561.	1.4	37
10	Valuing QALYs in Relation to Equity Considerations Using a Discrete Choice Experiment. <i>Pharmacoeconomics</i> , 2015, 33, 1289-1300.	3.3	31
11	The impact of the design of payment scales on the willingness to pay for health gains. <i>European Journal of Health Economics</i> , 2017, 18, 743-760.	2.8	22
12	Mitigating hypothetical bias in willingness to pay studies: post-estimation uncertainty and anchoring on irrelevant information. <i>European Journal of Health Economics</i> , 2019, 20, 75-82.	2.8	9
13	Discounting future health gains: an empirical enquiry into the influence of growing life expectancy. <i>Health Economics (United Kingdom)</i> , 2011, 20, 111-119.	1.7	5
14	Pricing and Reimbursement of Patent-Protected Medicines: Challenges and Lessons from South-Eastern Europe. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 915-927.	2.1	5
15	Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer. <i>European Journal of Health Economics</i> , 2021, 22, 393-403.	2.8	3
16	Budget Impact Analysis of Pharmacist-Led Medication Management in Cardiovascular and Type 2 Diabetic Patients. <i>Healthcare (Switzerland)</i> , 2022, 10, 722.	2.0	1
17	PHP46 WTP FOR A QALY: THE INDIVIDUAL PERSPECTIVE. <i>Value in Health</i> , 2009, 12, A245-A246.	0.3	0
18	Economic Evaluations of Personalized Health Technologies: An Overview of Emerging Issues. <i>Europeanization and Globalization</i> , 2016, , 107-135.	0.1	0